MedTrace Logo

Oral Immunotherapy for Childhood Egg Allergy

NCT00461097 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2017-12-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if oral immunotherapy (OIT) will desensitize a child with an allergy to egg and eventually lead to the development of tolerance to egg.

Conditions

Interventions

DRUG

Egg oral immunotherapy

Egg white solid powder

DRUG

Control Group

Placebo for egg white solid

Sponsors & Collaborators

  • Consortium of Food Allergy Research

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Wesley Burks, MD · University of North Carolina

  • Stacie Jones, MD · Allergy/Immunology Department, Arkansas Children's Hospital

  • Robert Wood, MD · Johns Hopkins University

  • Scott Sicherer, MD · Icahn School of Medicine at Mount Sinai

  • David Fleischer, MD · National Jewish Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00461097 on ClinicalTrials.gov